All In Biotech

Drug Trial Radar · NCT03514511

Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis

Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEO 138559 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

47

Actual

Start

May 7, 2018

Primary completion

Mar 2, 2021

Study completion Mar 2, 2021

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
May 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this trial is to investigate the safety and tolerability of LEO 138559 in healthy subjects and subjects with moderate to severe atopic dermatitis. The secondary objective of this trial is to study the pharmacokinetics and pharmacodynamics following administration of LEO 138559 to healthy subjects and subjects with moderate to severe atopic dermatitis. Healthy subjects will be exposed to 7 different dose regimens of LEO 138559 (one dose regimen per subject). Subjects with moderate to severe atopic dermatitis will be exposed to 2 different dose regimens of LEO 138559 (one dose regimen per subject).

Conditions

  • Atopic Dermatitis

Interventions

  • LEO 138559Drug

    LEO 138559 is a compound in development at LEO Pharma A/S

  • LEO 138559 placeboDrug

    LEO 138559 placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of LEO 138559 - numbers of subjects with adverse eventsTime frame: Day 1 to Day 120
  2. Safety of LEO 138559 - number of adverse eventsTime frame: Day 1 to Day 120
  3. Tolerability of LEO 138559 - number of local site reactionsTime frame: Day 1 to Day 120

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational site

    Leeds, United Kingdom

  • Investigational site

    Liverpool, United Kingdom

  • LEO Pharma investigational site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.